

GENERAL OBJECTIVE OF THE JATC

Support the implementation of the Tobacco Products Directive throughout the 28 EU MS

The TPD aims to preserve a high level of European public health and support the functioning of the internal market of tobacco products in the EU

Provide regulation of

- tobacco products
- novel tobacco products
- electronic cigarette products

The JATC is a collaborative action between the European Commission and the EU Member States built on evidence-based tobacco control policies with the overarching aim to be implemented at a national, regional and European level in order to improve Public Health protection in the EU.

SPECIFIC AIMS OF THE PROJECT

- Support the dissemination of information to the target groups
- Enhance the ease of access to the data collected, through the EU Common Entry Gate
- Monitor and provide support to the tasks of tobacco and e-cigarette products regulations
- Assist EU MS networking and enhance collaborations between laboratories for tobacco evaluation
- Support EU MS in the process of monitoring and updating priority additives
- Integrate the JATC results into national policies

TARGET GROUPS

- EU Regulators and national policymakers
- International and National Tobacco control stakeholders
- Researchers
- General public

ORGANIZATIONAL STRUCTURE

 COORDINATION TEAM
 HELLENIC CANCER SOCIETY

 STEERING COMMITTEE
 WORK PACKAGE LEADERS

 CONSORTIUM MEETING
 ALL PARTNERS

COORDINATION TEAM

| Project Coordinator | Prof. Panagiotis Behrakis |
|---|---------------------------|
| Project Associate Coordinators Dr. Constantine Varo | |
| | Dr. Anna Tzortzi |
| Project Manager | Dimitris Kagkos |
| Project Secretariat | Penelope Stambouli |

PROJECT MANAGEMENT STRUCTURE



PARTICIPANTS 31 PROJECT PARTNERS/INSTITUTIONS

1 | **HCS**

Hellenic Cancer Society, Greece

2 | **AGES**

Austrian Agency for Health and Food Safety, Austria

3 | **BHTC**

Federal Public Service Health, Belgium

4 | NCPHA

National Center of Public Health and Analyses, Bulgaria

5 | MoH-CY

Ministry of Health, Cyprus

6 | **SIK** Danish Safety Technology Authority

7 | **TA** Estonian Health Board

8 | ANSES

French agency for food, environmental and occupational health & safety

9 | **BfR**

Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung), Germany

10 | APTL-CERTH

Aerosol & Particle Technology Laboratory, Chemical Process & Energy Resources Institute, Centre for Research & Technology, Greece

11 | **SU-(SE)** Semmelweis University, Hungary

12 | **DOHI** Directorate of Health, Iceland

13 | **HSE** Health Service Executive, Ireland

14 | IRCCS-IRFMN Istituto di Ricerche Farmacologiche "Mario Negri", Italy

15 | ISS National Institute of Health Istituto Superiore di Sanita, Italy

16 | **MOH-IT** Ministry of Health, Italy

17 | HI Health Inspectorate, Ministry of Health, Latvia

18 | NTAKD Drug, tobacco and alcohol control department, Lithuania

19 | **NVSPL**

National Public Health Surveillance Laboratory, Lithuania

20 | **DEH**

Environmental Health Directorate, Malta

21 | **RIVM**

National Institute for Public Health and the Environment, The Netherlands

22 | **NIPH**

Institute of Public Health, Norway

23 | NOMA Norwegian Medicines Agency

24 | MS-DGS Directorate General of Health, Portugal

W/P LEADERS

1 | HCS Hellenic Cancer Society, Greece 2 | AGES Austrian Agency for Health and Food Safety, Austria 5 | MoH CY Ministry of Health, Cyprus 6 | SIK Danish Safety Technology Authority 14 | IRCCS - IRFMN Istituto di Ricerche Farmacologiche "Mario Negri", Italy

25 | BATUT-IPHS

Institute of Public Health, Serbia 26 | MZLOH National Laboratory of Health, Environment and Food, Slovenia

27 | ICO Catalan Institute of Oncology, Spain– included affiliated partner IDIBELL

28 | CSJA Consejería de Salud Junta de Andalucía, Spain – including affiliated partners AGAPA and FPS

29 | FOHM The Public Health Agency, Sweden

30 | UK-DH Department of Health, UK

31 | HTC Hellenic Thoracic Society, Greece

21 | **RIVM**

National Institute for Public Health and the Environment, The Netherlands

25 | **BATUT-IPHS** Institute of Public Health, Serbia

27 | ICO Catalan Institute of Oncology, Spain- included affiliated partner IDIBELL

COLLABORATING STAKEHOLDERS

| INSTITUTION | COUNTRY |
|---|-------------|
| WHO - FCTC | Switzerland |
| European Respiratory Society (ERS) | Switzerland |
| CHEST | USA |
| Institute of Public Health-ACG | Greece |
| Aer Pur Romania | Romania |
| National Supervisory Authority for Welfare and Health (Valvira) | Finland |
| Bureau for Chemical Substances | Poland |
| Norwegian Directorate of Health | Norway |
| National Center for Public Health | Moldova |
| Universitat Internacional de Catalunya (UIC-Barcelona) | Spain |
| Individual Expert | Hungary |
| Lithuanian University of Health Sciences | Lithuania |
| Athens Medical Center | Greece |

WORK PACKAGES 1-9

| 01 нсs | Coordination Hellenic Cancer Society | |
|---------------------|--|--|
| 02 batut | Dissemination HCS, MoHCY, SE | |
| 03 Ages | Evaluation HCS | |
| 04 MoH-CY | Integration into National Policies & Sustainability HCS,NCPHA, MoHCY, TA, ANSES, BfR, SE, HSE, IRFMN, NTAKD, CSJA | |
| 05 sik | Common Entry Gate (CEG) data extraction and handling HCS, AGES, BHTC, NCPA, SIK, TA, ANSES, MOHIT, NTAKD, NOMA, MS, NLZOH, CSJA, FOHM, UK-DOH | |
| 06 ICO | Tobbaco Product Evaluation HCS, AGES, BHTC, SIK, ANSES, BFR, CERTH, HTS, HSE, IRFMN, ISS, MOHIT, NTAKD, RIVM, NIPH, MS, NLZOH, ICO, CSJA, FOHM, UK-DOH | |
| 07 нсs | E-Cigarette Product Evaluation HCS, AGES, BHTC, ANSES, BfR, CERTH, HTS, DOHI, HSE, IRFMN, ISS, MOH-IT, HI, NTAKD, RIVM, NIPH, NOMA, MS, ICO, CSJA, FOHM, UK-DOH | |
| 08 irfmn | Laboratory Verfication, Collaboration & Analyses HCS, AGES ,BfR, CERTH, HTS, IRFMN , NVSPL, RIVM, NLZOH, CSJA | |
| 09 rivm | Additives Subject to Enhanced Reporting Obligations HCS ,SIK, ANSES, BfR, IRFMN, ISS, RIVM, NIPH, CSJA, FOHM | |

EXPECTED OUTCOMES

- Increased EU MS implementation of the TPD through the provision of support and technical/ scientific capacity to EU regulators
- Increased EU MS regulator training through the provision of capacity building (toolkits, e-learning)
- Common approach on handling tobacco products evidence based decisions across EU MS, within the context of their national legislative approach
- Increased data sharing and collaborations between EU MS on tobacco product regulatory science
- Responses to questions on "burning topics" as brought forward by EU MS regulators
- Increased literacy on tobacco products design, constituents and toxicity by regulators and the public

- Close monitoring of e-cigarette compliance to the TPD across the EU MS
- Increased knowledge of e-cigarette design parameters, ingredients and emissions
- Enhanced collaborations between EU MS laboratories for tobacco products ingredients and emissions measurements
- Increased scientific scrutiny and decisions on potential priority additives within tobacco products
- Greater access to data on tobacco products and e-cigarettes, in order to fuel general population awareness and enhance research and policy actions. The provision of such public data will be an unprecedented opportunity for tobacco control research.



www.jaotc.eu

Coordination Team: @ jatc@researchlab.gr

The content of this leaflet represents the views of the author only and his/ her soe responsibility; it can not be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.



"This activity is part of the project / joint action '761297 / JATC' which has received funding from the European Union's Health Programme (2014-2020)."